アステラス製薬（4503） – Supplementary Documents (Q3/FY2021)

Supplementary Documents [IFRS] Financial results for the first nine months of the fiscal year 2021 (FY2021) Astellas Pharma Inc. – Q3/FY2021 Financial Results Nine months ended December 31, 2021 Three months ended December 31, 2021 – Pipeline list Cautionary Notes – In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice. S-1[Nine months ended December 31, 2021]1. Consolidated Results (Full Basis)RevenueCost of salesGross profitSG&A expenses XTANDI co-promotion fee in the United states Personnel expenses Advertising and Sales Promotion and OtherR&D expensesAmortisation of intangible assetsGain on divestiture of intangible assetsShare of profit (loss) of investments accounted for using equity method Other income Net foreign exchange gains Fair value remeasurements on contingent considerationOther expense Impairment losses Restructuring costs Net foreign exchange losses Fair value remeasurements on contingent considerationOperating profitFY20FY21ChangeUnit: B¥Change(%) APR. – DEC. APR. – DEC.992.3 194.1 19.6%798.2406.441.0%108.7143.0154.7177.617.9% 20.2 24.1 2.0 4.2 0.6 2.2 54.9 26.7 18.3 – 8.7 169.417.1%2.34.3167.416.9%34.9132.513.4%164.5940.9187.720.0%753.2363.038.6%90.2133.9139.0168.817.9% 17.3 – -0.3 7.0 – 3.9 51.3 36.7 2.9 4.2 4.4 159.516.9%6.51.7164.217.5%31.3132.914.1%155.9 51.46.4 45.043.4 18.59.215.78.8 3.024.12.3-2.80.6-1.63.6-9.915.4-4.24.39.9 -4.22.53.2 3.6-0.4Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue 5.5%3.4%6.0%11.9%20.5%6.9%11.3%5.2%17.1%—40.3%–42.7%6.9%-27.1%542.0%-100.0%97.8%6.2%-64.5%144.8%1.9%11.5%-0.3% 8.65.5%Finance incomeFinance expensesProfit before taxIncome tax expenseProfitComprehensive incomeForecastsFY21Full Year Change fromFY20Change(%) 1,323.05.9% 541.040.9% 242.018.3%7.3%7.8% 218.016.5% 216.016.3% 174.013.1%60.2%48.6%44.3%FY20Full Year 1,249.5246.119.7%1,003.5504.340.4%120.2182.2201.9224.518.0% 23.8 – 0.5 7.6 – 3.6 123.0 101.7 9.3 2.3 6.0 136.110.9%11.62.3145.311.6%24.7120.69.7%181.5 S-22. Consolidated Results (Core Basis)RevenueCost of salesGross profitSG&A expenses XTANDI co-promotion fee in the United states Personnel expenses Advertising and Sales Promotion and OtherR&D expensesAmortisation of intangible assetsGain on divestiture of intangible assetsShare of profit (loss) of investments accounted for using equity methodOperating profitRatio to Revenue Unit: B¥Change(%)FY20FY21Change APR. – DEC. APR. – DEC.992.3 194.1 19.6%798.2406.441.0%108.7143.0154.7177.617.9%20.224.12.0220.022.2%2.34.3218.122.0%48.4169.717.1%940.9187.720.0%753.2363.038.6%90.2133.9139.0168.817.9% 17.3 – -0.3203.7 21.7%6.51.7208.522.2%41.9166.617.7% 51.46.4 45.043.4 18.59.215.78.8 3.024.12.316.3 -4.22.59.6 6.53.0Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue 5.5%3.4%6.0%11.9%20.5%6.9%11.3%5.2%17.1%–8.0%-64.5%144.8%4.6%15.6%1.8%FY20FY21APR. – DEC.Ave. APR. – DEC.Ave.111 131 106122FY20End 111130Unit: yenFY21Q3 End 115131FY20Full Year 1,249.5246.119.7%1,003.5504.340.4%120.2182.2201.9224.518.0% 23.8 – 0.5251.4 20.1%11.62.3260.620.9%50.7209.916.8% FY20Full Year 106124ForecastsFY21Full Year Change fromFY20Change(%) 1,323.05.9% 541.040.9% 242.018.3% 270.020.4%7.3%7.8%7.4% 213.016.1%1.5%ForecastsFY21Full Year 110130Finance incomeFinance expensesProfit before taxIncome tax expenseProfit 3. Exchange RateUSD/YenEUR/Yen* Fx impacts: Revenue +42.8 billion yen and Core operating profit +15.4 billion yen * Fx impact on elimination of unrealized gain: COGs ratio +0.2ppt S-34. Reconciliation of Full Basis to Core BasisRevenueCost of salesGross profitSG&A expensesR&D expensesAmortisation of intangible assetsGain on divestiture of intangible assetsShare of profit (loss) of investments accountedfor using equity methodOther income *Other expenses *Operating profitFinance incomeFinance expensesProfit before taxIncome tax expenseProfitFY20APR. – DEC.Adjustment – – – – – – -Full basis940.9 187.7 753.2 363.0 168.8 17.3 -Core basisFull basis 940.9 187.7 753.2 363.0 168.8 17.3 – 992.3194.1798.2406.4177.620.224.1FY21APR. – DEC.Adjustment- – — – – -Unit: B¥Core basis 992.3194.1798.2406.4177.620.224.1 -0.3 – -0.3 2.0 – 2.0 7.051.3159.56.51.7164.231.3132.9-7.0 -51.3 44.3 – – 44.3 10.6 33.7 – – 203.76.51.7208.541.9166.6 4.254.9169.42.34.3167.434.9132.5-4.2 -54.9 50.7 – – 50.7 13.5 37.2- – 220.02.34.3218.148.4169.7* “Other income” and “Other expenses” are excluded from Core basis results. “Other income” and “Other expenses” include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.S-45. Revenue by RegionRevenueJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsOthers APR. – DEC. APR. – DEC.992.3 203.2 20.5%407.941.1%239.224.1%50.35.1%83.08.4%8.60.9%940.9221.823.6%355.837.8%218.023.2%43.84.7%87.69.3%13.91.5% Ratio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueFY20FY21ChangeUnit: B¥ 51.4-18.6Change(%)5.5%-8.4% 52.114.7%FY20Full Year 1,249.5279.122.3%473.237.9%293.223.5%59.34.7%111.18.9%33.62.7%ForecastsFY21Full Year 1,323.0252.119.0%552.541.8%322.124.3%65.04.9%122.59.3%8.90.7%Change fromFY20Change(%)5.9%-9.7%16.8%9.9%9.6%10.2%-73.5% 21.39.8% 6.514.8% -4.6-5.3% -5.3-38.0% – Established Markets: Europe, Canada, Australia- Greater China: China, Hong Kong, Taiwan- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc. 6. Addition to Property, Plant and Equipment　Depreciation/AmortisationAddition to Property, Plant and EquipmentDepreciation (PP&E)ConsolidatedConsolidatedConsolidatedAmortisation of Intangible Assets (incl. software, etc.)- Addition to Property, Plant and Equipment does not include right-of-use assetFY20FY21ChangeAPR. – DEC. APR. – DEC.Change(%)FY20Full YearUnit: B¥ 23.9 22.3 -1.5 33.7 34.0 30.1 30.3 0.3 40.0 42.0-6.4%0.9% 24.0 28.3 4.217.6% 32.7 38.016.3%ForecastsFY21Full YearChange fromFY20Change(%)0.9%5.0%S-57. Sales of major products1) GlobalXTANDIXOSPATAPADCEVEVRENZOPrografUnited Statesex-US Japan Established Markets Greater China International MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsJapanUnited StatesEstablished MarketsJapanEstablished MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsBetanis/Myrabetriq/BETMIGAJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsVesicareFY20FY21ChangeUnit: B¥Change(%)APR. – DEC. APR. – DEC.411.6 342.7215.8 180.0195.8 162.736.5 31.0128.8 108.85.5 3.225.0 19.625.7 17.63.1 2.914.4 11.66.5 3.11.3 0.00.4 0.014.6 9.40.5 -14.0 9.40.0 -2.1 0.72.0 0.70.1 -126.9 122.329.2 26.661.9 65.927.6 21.92.0 1.66.2 6.317.9 24.78.6 14.51.4 1.94.2 4.60.8 0.82.9 2.8141.1 138.330.3 32.17.6 9.451.9 47.629.8 24.821.5 24.4- 9.3 68.935.733.15.520.02.35.48.10.22.83.41.30.35.20.54.60.01.41.30.14.62.6-4.05.70.5-0.1-6.7-5.9-0.5-0.40.00.12.8-1.8-1.84.35.0-2.9-9.320.1%19.8%20.4%17.6%18.4%70.6%27.4%45.8%6.5%24.7%107.1%-716.7%55.7%-49.5%-198.6%181.2%-3.8%9.6%-6.1%25.9%29.2%-1.1%-27.3%-40.7%-26.4%-9.2%3.1%3.7%2.0%-5.6%-19.7%9.1%20.2%-11.8%-FY20Full Year 458.4 238.6 219.8 40.2 149.3 4.9 25.5 23.8 3.8 15.5 4.4 0.0 0.2 12.8 – 12.8 – 1.1 1.1 – 163.6 35.1 88.0 29.9 2.2 8.5 31.6 18.5 2.2 6.2 1.0 3.7 182.7 40.7 11.8 64.2 34.2 31.7 9.5ForecastsFY21Full Year 554.1290.2264.047.1176.08.232.635.44.419.29.41.70.620.70.819.70.27.24.13.2176.336.793.035.72.78.218.97.61.55.21.03.6185.738.29.167.337.933.2-Change fromFY20Change(%)20.9%21.6%20.1%17.2%17.9%68.2%28.0%48.3%15.9%24.1%114.8%-315.8%61.4%-53.4%-540.8%262.8%-7.8%4.5%5.7%19.7%23.1%-3.6%-40.3%-59.0%-33.2%-17.1%1.5%-2.4%1.7%-6.3%-23.1%5.0%10.8%4.8%-Eligard- Sales of products in Japan are shown in a gross sales basis- Established Markets: Europe, Canada, Australia- Greater China: China, Hong Kong, Taiwan- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.- PADCEV (United States): Co-promotion revenue from Seagen- Astellas’ EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.S-62) Revenue by region　(1) JapanXTANDIXOSPATAPADCEVEVRENZOBetanis VesicarePrograf (Including Graceptor)HarnalFunguard

Suglat [Family] SujanuRepathaLinzessBLINCYTOEVENITYSmyrafCelecox Geninax VaccinesGonax CimziaLipitorMysleeTotal Rx Sales In Japanese market- Sales of products in Japan are shown in a gross sales basis.Unit: B¥Change(%)FY20FY21ChangeAPR. – DEC. APR. – DEC.36.5 31.03.1 2.90.5 -2.0 0.729.2 26.68.6 14.530.3 32.12.0 2.41.4 4.0 5.50.20.51.32.6-5.9-1.8-0.4-2.7 21.68.73.94.93.419.01.116.92.07.94.07.78.46.2219.6 23.7 9.7 4.5 5.4 4.7 23.3 1.9 – 2.1 5.2 3.9 8.7 – 5.5 201.7 2.11.00.60.51.34.30.7-16.90.1-2.7-0.11.0-8.4-0.7-17.917.6%6.5%-181.2%9.6%-40.7%-5.6%-15.4%-66.2%9.8%11.5%14.3%10.7%39.5%22.4%63.6%-4.6%-34.0%-1.4%12.8%–10.6%-8.2%FY20Full Year 40.2 3.8 – 1.1 35.1 18.5 40.7 3.0 4.4 27.911.35.16.44.524.81.718.92.57.95.110.010.67.8276.6ForecastsFY21Full Year 47.14.40.84.136.77.638.22.41.5Change fromFY20Change(%)17.2%15.9%-262.8%4.5%-59.0%-6.3%-19.9%-65.3% 30.59.4% 7.09.4% 3.189.3% 3.15.25.0 6.9250.324.2%-34.6%-1.7%-12.3%-9.5%S-7　(2) United StatesRevenueXTANDIXOSPATAPADCEVMyrbetriqVesicarePrografMYCAMINEAmBisomeCRESEMBALexiscan　(3) Established MarketsRevenueXTANDIXOSPATAPADCEVEVRENZO BETMIGA Vesicare Prograf Omnic MYCAMINE Eligard- Established Markets: Europe, Canada, AustraliaUnit: M$Change(%)Unit: M€Change(%)FY20FY21ChangeAPR. – DEC. APR. – DEC.3,672 1,942 130 126 557 13 68 41 101 143 551 3,3531,6971098862118896385120456 3192452138-64-5-21-22162295FY20FY21ChangeAPR. – DEC. APR. – DEC. 1,832 1,781 986 889 50 26 0 – 1 – 212 179 32 38 397 389 51 4918 36 – 64 51 98 24 0 1 32 -6 9 2 -18 -649.5%14.5%19.1%42.8%-10.3%-29.7%-23.3%-34.7%18.6%18.6%20.8%2.9%11.0%94.1%–18.0%-14.9%2.2%4.4%-49.9%-FY20Full Year 4,4622,2501461218292011283114160623FY20Full Year 2,370 1,207 36 – – 241 50 519 65 45 64ForecastsFY21Full Year 5,0222,638175179845138345127185732FY21Full Year 2,477 1,354 73 1 24 275 40 518 6523 -Change fromFY20Change(%)12.6%17.3%19.6%47.9%1.9%-35.6%-25.8%-45.3%12.3%16.0%17.5%4.5%12.2%104.4%–13.9%-21.1%-0.1%0.0%-48.0%-Change(%)S-8　(4) Greater ChinaRevenue- Greater China: China, Hong Kong, Taiwan　(5) International MarketsRevenueXTANDIXOSPATA BETMIGA Vesicare Prograf Harnal MYCAMINE FeburicXTANDIXOSPATA BETMIGA Vesicare Prograf Harnal MYCAMINEUnit: B¥Change(%)FY20FY21ChangeAPR. – DEC. APR. – DEC.50.3 5.5 1.3 2.0 0.8 29.8 6.1 2.1 2.1 43.83.20.01.60.824.88.91.81.9 6.52.31.30.50.05.0-2.80.30.1Unit: B¥Change(%)FY20FY21ChangeAPR. – DEC. APR. – DEC.83.0 25.0 0.4 6.2 2.9 21.5 12.7 4.7 87.619.60.06.32.824.411.63.1 -4.65.40.3-0.10.1-2.91.11.614.8%70.6%-29.2%3.1%20.2%-31.6%17.2%7.6%-5.3%27.4%716.7%-1.1%3.7%-11.8%9.1%49.8%FY20Full Year 59.34.90.02.21.034.210.82.52.6FY20Full Year 111.125.50.28.53.731.715.14.4ForecastsFY21Full Year 65.08.21.72.71.037.97.92.22.7ForecastsFY21Full Year 122.532.60.68.23.633.216.26.1Change fromFY20Change(%)9.6%68.2%-23.1%1.5%10.8%-27.5%-13.0%1.9%10.2%28.0%315.8%-3.6%-2.4%4.8%7.2%40.2%Change fromFY20Change(%)- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc. S-98. Consolidated statements of financial positionAssetsNon-current assetsProperty, plant and equipmentGoodwillIntangible assetsTrade and other receivablesInvestments accounted for using equity methodDeferred tax assetsOther financial assetsOther non-current assetsCurrent assetsInventoriesTrade and other receivablesIncome tax receivableOther financial assetsOther current assetsCash and cash equivalentsEquity and LiabilitiesEquityEquity attributable to owners of the parentShare capitalCapital surplusTreasury sharesRetained earningsOther components of equityLiabilitiesNon-current liabilitiesTrade and other payablesDeferred tax liabilitiesRetirement benefit liabilitiesProvisionsOther financial liabilitiesOther non-current liabilitiesCurrent liabilitiesTrade and other payablesIncome tax payableProvisionsOther financial liabilitiesOther current liabilitiesFY20End 2,273.61,401.0264.6284.0651.433.97.154.295.99.9872.6164.1343.214.05.619.7326.1FY20End 2,273.61,386.11,386.1103.0177.8-15.4953.3167.4 887.5295.10.418.239.05.8199.032.8592.4124.88.422.2148.2288.9FY21Q3 End 2,356.21,416.9267.8293.6652.330.410.958.593.410.1939.3151.6373.916.817.928.9350.2FY21Q3 End 2,356.21,466.31,466.3103.0179.0-15.5999.6200.1 890.0292.00.710.637.94.3201.536.9598.0136.922.014.0108.7316.4Unit: B¥Change 82.615.93.29.60.8-3.63.84.3-2.40.266.7-12.530.72.812.39.324.1Unit: B¥Change82.6 80.2 80.2 – 1.2 -0.1 46.4 32.8 2.4-3.20.3-7.5-1.0-1.52.54.15.612.113.6-8.2-39.527.6S-10[Three months ended December 31, 2021]1. Consolidated Results (Full Basis)RevenueCost of salesGross profitSG&A expensesRatio to Revenue Ratio to Revenue Ratio to Revenue XTANDI co-promotion fee in the United states Personnel expenses Advertising and Sales Promotion and OtherR&D expensesAmortisation of intangible assetsGain on divestiture of intangible assetsShare of profit (loss) of investments accounted for using equity method Other income Net foreign exchange gains Fair value remeasurements on contingent considerationOther expense Impairment losses Restructuring costs Net foreign exchange losses Fair value remeasurements on contingent considerationOperating profitFinance incomeFinance expensesProfit before taxIncome tax expenseProfitComprehensive incomeRatio to Revenue Ratio to Revenue Ratio to Revenue APR.-JUN.(Quarterly) 326.162.219.1%263.9137.142.0%34.549.053.658.317.9% 6.0 – 0.3 0.4 0.3 – 27.1 26.1 0.6 – 0.0 36.111.1%1.51.735.811.0%5.130.79.4%36.2 Change(%)FY21Change(%)Change(%)JUL.-SEP.(Quarterly) 325.562.519.2%263.0133.441.0%36.647.049.860.718.7% 6.4 – 0.0 2.4 2.0 0.0 10.8 0.0 2.0 – 8.7 54.116.6%0.41.353.316.4%12.340.912.6%33.9 6.2%4.3%6.7%13.5%9.4%7.3%23.0%1.8%1.8%—82.0%-70.5%-465.2%690.7%–91.4%-40.7%284.3%79.6%-40.5%-47.7%-39.1%-34.7%Unit: B¥OCT.-DEC.(Quarterly) 340.669.420.4%271.3135.939.9%37.647.051.358.617.2% 7.9 24.1 1.7 3.1 – 2.2 18.6 0.7 15.8 1.7 0.0 79.223.3%0.41.378.323.0%17.460.917.9%94.5 5.5%4.4%5.8%9.9%24.8%5.5%4.9%11.6%12.7%—24.6%–99.9%-75.4%-100.0%116.7%-100.0%109.5%107.5%-85.9%363.6%84.6%91.9%82.5%49.4%4.7%1.7%5.5%12.4%28.0%7.8%7.0%2.6%37.0%—20.8%-100.0%-292.3%-68.5%713.6%–92.6%9.1%-86.4%150.7%4.2%15.8%1.3%21.4%S-112. Consolidated Results (Core Basis) XTANDI co-promotion fee in the United states Personnel expenses Advertising and Sales Promotion and OtherR&D expensesAmortisation of intangible assetsGain on divestiture of intangible assetsShare of profit (loss) of investments accounted for using equity methodOperating profitRatio to Revenue RevenueCost of salesGross profitSG&A expensesFinance incomeFinance expensesProfit before TaxIncome tax expenseProfit FY21Change(%)Change(%)OCT.-DEC.(Quarterly)Change(%)APR.-JUN.(Quarterly) 326.162.219.1%263.9137.142.0%34.549.053.658.317.9% 6.0 – 0.362.8 19.3%1.51.762.619.2%13.349.215.1% Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue Ratio to Revenue JUL.-SEP.(Quarterly) 325.562.519.2%263.0133.441.0%36.647.049.860.718.7% 6.4 – 0.062.5 19.2%0.41.361.718.9%12.149.515.2% 6.2%4.3%6.7%13.5%9.4%7.3%23.0%1.8%1.8%—0.9%284.3%79.6%-0.4%23.3%-5.3%Unit: B¥340.669.420.4%271.3135.939.9%37.647.051.358.617.2%7.924.11.794.827.8%0.41.393.927.6%22.970.920.8%5.5%4.4% 5.8%9.9% 24.8%5.5%4.9%11.6% 12.7%—6.6% -85.9%363.6%-11.6% -21.9%-8.6% 4.7%1.7%5.5%12.4%28.0%7.8%7.0%2.6%37.0%–29.0%-86.4%150.7%23.5%47.8%17.3%S-123. Revenue by Region RevenueJapanUnited StatesAPR.-JUN.(Quarterly) Change(%)JUL.-SEP.(Quarterly)Change(%)OCT.-DEC.(Quarterly)Change(%)6.2%-13.2% 5.5%-5.2% 14.1% 14.1% Ratio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to RevenueRatio to Revenue326.167.520.7%133.641.0%78.023.9%16.45.0%27.88.5%2.80.9%Established Markets 21.8% 6.0% Greater China 15.5% 8.3% International Markets -8.1% 3.7% Others -21.9% -55.9% – Established Markets: Europe, Canada, Australia- Greater China: China, Hong Kong, Taiwan- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.FY21325.563.019.4%136.541.9%79.424.4%16.65.1%27.58.4%2.50.8%FY214. Addition to Property, Plant and Equipment　　Depreciation/AmortisationAddition to Property, Plant and EquipmentDepreciation (PP&E)ConsolidatedConsolidatedConsolidatedAmortisation of Intangible Assets (incl. software, etc.)- Addition to Property, Plant and Equipment does not include right-of-use asset.APR.-JUN.(Quarterly)Change(%)JUL.-SEP.(Quarterly)Change(%)OCT.-DEC.(Quarterly)Change(%) 5.2-27.3% 7.84.9% 9.3 9.9-0.6% 10.0-0.1% 10.4 8.22.6% 9.012.7% 11.137.4%Unit: B¥340.672.721.3%137.840.5%81.924.0%17.35.1%27.78.1%3.31.0%Unit: B¥4.7%-6.3%15.7%3.5%21.2%-10.3%-28.1%0.3%3.5%S-135. Sales of major products1) GlobalXTANDIXOSPATAPADCEVEVRENZOPrografUnited Statesex-US Japan Established Markets Greater China International MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsJapanUnited StatesEstablished MarketsJapanEstablished MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsBetanis/Myrabetriq/BETMIGAJapanUnited StatesEstablished MarketsGreater ChinaInternational MarketsVesicareChange(%)FY21Change(%)Change(%)APR.-JUN.(Quarterly) 132.9 68.4 64.5 12.0 42.8 1.9 7.8 8.3 1.1 4.6 2.0 0.5 0.1 4.2 – 4.2 – 0.6 0.6 – 44.0 9.8 22.8 8.5 0.7 2.2 7.4 4.6 0.2 1.4 0.3 0.9 45.2 10.2 2.1 16.2 9.6 7.0JUL.-SEP.(Quarterly) 134.7 72.7 62.0 11.5 41.1 1.7 7.6 8.2 1.0 4.4 2.1 0.5 0.1 4.9 – 4.9 – 0.8 0.7 0.1 40.4 8.9 19.3 9.4 0.6 2.3 5.4 2.0 0.7 1.5 0.2 1.0 47.1 9.4 2.7 18.2 9.9 6.918.7%9.1%31.0%18.5%36.1%165.1%12.2%47.7%6.6%26.9%99.4%–41.9%-41.9%-282.9%282.9%-8.8%16.2%-0.5%29.4%56.9%5.8%-4.4%-7.7%-39.4%14.4%22.3%-3.9%-0.3%-7.9%-40.8%17.0%22.9%-21.7%Unit: B¥OCT.-DEC.(Quarterly) 143.974.669.312.944.91.99.69.21.05.42.40.30.15.50.54.90.00.70.70.042.510.519.99.70.71.85.22.10.51.20.31.148.810.72.817.510.37.618.6%24.5%12.4%17.9%9.9%11.1%18.8%53.0%19.0%21.1%156.3%-785.7%60.8%-60.8%-352.1%288.3%-2.2%8.5%-8.9%21.0%23.5%15.3%-36.6%-55.3%-46.3%-6.6%-10.2%6.0%6.4%-5.3%-11.7%9.9%17.7%8.9%22.8%26.6%18.9%16.6%12.4%97.9%52.9%38.4%-3.5%25.8%81.8%-321.1%63.2%-45.9%-91.3%88.2%-0.5%4.8%-9.1%27.9%15.0%-21.7%-38.8%-59.9%67.6%-29.0%-0.4%8.4%0.2%-3.5%-1.7%1.8%20.1%-16.4%- Sales of products in Japan are shown in a gross sales basis- Established Markets: Europe, Canada, Australia- Greater China: China, Hong Kong, Taiwan- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc. – PADCEV (United States): Co-promotion revenue from Seagen – Astellas’ EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc. S-142）Revenue by region　(1) JapanXTANDIXOSPATAPADCEVEVRENZOBetanis VesicarePrograf (Including Graceptor)HarnalFunguard

Suglat [Family］ SujanuRepathaLinzessBLINCYTOEVENITYSmyrafGeninax VaccinesGonax CimziaMysleeTotal Rx Sales In Japanese market- Sales of products in Japan are shown in a gross sales basis.APR.-JUN.(Quarterly) 12.0 1.1 – 0.6 9.8 4.6 10.2 0.7 0.4 7.93.21.51.81.47.00.60.70.01.32.81.867.0Change(%)JUL.-SEP.(Quarterly) 11.5 1.0 – 0.7 8.9 2.0 9.4 0.6 0.418.5%6.6%-282.9%16.2%-7.7%-7.9%-20.2%-70.7%10.9%13.6%25.3%12.9%17.6%1.6%179.6%15.4%0.0%-20.3%12.3%-11.4%-12.9% 7.53.11.41.71.57.40.60.62.01.32.81.862.6FY21Change(%)Change(%)Unit: B¥OCT.-DEC.(Quarterly) 12.91.00.50.710.52.110.70.70.517.9%19.0%-288.3%8.5%-55.3%-5.3%-15.1%-68.3%11.8%15.2%9.8%11.7%52.2%28.8%52.3%19.3%-29.0%3.4%14.1%-10.7%-5.3% 8.33.41.62.01.88.80.70.83.21.33.11.972.016.6%-3.5%-88.2%4.8%-59.9%-3.5%-10.6%-58.0%7.1%6.5%9.5%7.9%50.0%39.2%22.2%-11.1%-36.5%20.8%12.1%-9.9%-5.9%S-15　(2) United StatesRevenueXTANDIXOSPATAPADCEVMyrbetriqVesicarePrografMYCAMINEAmbisomeCRESEMBALexiscanXTANDIXOSPATAPADCEVEVRENZO BETMIGA Vesicare Prograf Omnic MYCAMINE　(3) Established MarketsRevenue- Established Markets: Europe, Canada, AustraliaAPR.-JUN.(Quarterly) 1,221 625 42 38 208 2 19 14 30 45 196Change(%)JUL.-SEP.(Quarterly) 1,240 661 40 45 175 6 24 16 38 49 18612.1%7.2%24.7%39.5%-2.2%-40.4%-41.8%-40.4%35.9%25.8%77.1%APR.-JUN.(Quarterly) 591 325 15 – – 65 11 123 17 7Change(%)JUL.-SEP.(Quarterly) 612 317 16 – 1 72 12 140 19 69.4%22.2%79.0%–16.2%2.7%5.1%12.2%-47.6%FY21Change(%)Change(%)Unit: M$OCT.-DEC.(Quarterly) 1,211 656 48 43 174 5 25 11 33 48 169Unit: M€OCT.-DEC.(Quarterly) 629 345 18 0 075 9 134 16 510.2%20.1%16.9%55.3%-12.2%-47.9%-14.9%-25.8%29.3%23.5%3.1%1.2%4.9%146.7%–15.4%-11.1%4.8%12.1%-47.7%6.3%16.4%16.3%34.4%-16.7%50.9%-9.6%-38.3%-2.3%8.4%2.3%-1.1%7.4%73.2%–22.4%-32.1%-2.7%-9.6%-54.9%FY21Change(%)Change(%)S-16(4) Greater ChinaRevenue- Greater China: China, Hong Kong, Taiwan(5) International MarketsRevenueXTANDIXOSPATA BETMIGA Vesicare Prograf Harnal MYCAMINE FeburicXTANDIXOSPATA BETMIGA Vesicare Prograf Harnal MYCAMINEAPR.-JUN.(Quarterly)Change(%)JUL.-SEP.(Quarterly)Change(%)OCT.-DEC.(Quarterly)Change(%)FY21FY2116.6 1.7 0.5 0.6 0.2 9.9 2.0 0.7 0.7 27.5 7.6 0.1 2.3 1.0 6.9 3.8 2.0 8.3%11.1%-23.5%-10.2%17.7%-33.4%1.7%15.0%3.7%18.8%785.7%15.3%6.0%8.9%-2.4%97.2%Unit: B¥17.3 1.9 0.3 0.7 0.3 10.3 2.1 0.8 0.7 27.7 9.6 0.1 1.8 1.1 7.6 4.6 1.1 Unit: B¥21.2%97.9%-15.0%-0.4%20.1%-3.6%28.2%-0.4%-10.3%52.9%321.1%-21.7%8.4%-16.4%30.4%-5.0%16.4 1.9 0.5 0.7 0.3 9.6 2.0 0.6 0.6 27.8 7.8 0.1 2.2 0.9 7.0 4.3 1.6 15.5%165.1%-56.9%22.3%22.9%-46.8%25.3%9.7%-8.1%12.2%-5.8%-3.9%-21.7%2.1%64.6%APR.-JUN.(Quarterly)Change(%)JUL.-SEP.(Quarterly)Change(%)OCT.-DEC.(Quarterly)Change(%)- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.S-17R&D Pipeline The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.As of Feb 2022Underlined items indicate changes from the previous announcement in Oct 2021.XTANDI and Strategic products (1/2)Generic nameCode No.(Brand name)enzalutamideMDV3100(XTANDI)gilteritinibASP2215(XOSPATA)Modality / TechnologyClassificationTarget diseasePhase *Licensor **RemarksSmall moleculeAndrogen receptor inhibitorMetastatic castration-sensitive prostate cancerChinaP-IIIPfizerSmall molecule FLT3 inhibitorPost-chemotherapy maintenanceacute myeloid leukemiaIn-houseenfortumab vedotinASG-22ME(PADCEV)Antibody-drug conjugate(ADC)Nectin-4 targeted ADCMetastatic urothelial cancer, PD-1/PD-L1 inhibitor andplatinum-containing chemotherapy pretreatedEuropeFiled (Mar 2021)In-house[Co-development withSeagen]Non-metastatic castration-sensitive prostate cancerP-IIIPost-hematopoietic stem cell transplant maintenanceacute myeloid leukemiaP-IIINewly diagnosed acute myeloid leukemiawith low intensity induction of chemotherapyNewly diagnosed acute myeloid leukemiawith high intensity induction of chemotherapyAcute myeloid leukemia in pediatric patientsMetastatic urothelial cancer, previously untreated(first line; combo with pembrolizumab)Muscle-invasive bladder cancer(combo with pembrolizumab)Other solid tumorsNon-muscle-invasive bladder cancerP-IIIP-IP-IIIP-IIIP-IIIP-IIIP-IIP-IS-18XTANDI and Strategic products (2/2)Generic nameCode No.(Brand name)Modality / TechnologyClassificationTarget diseasePhase *Licensor **RemarkszolbetuximabIMAB362AntibodyAnti-Claudin 18.2monoclonal antibodyGastric and gastroesophageal junctionadenocarcinomaIn-house(Ganymed)Small moleculeHIF-PH inhibitorChemotherapy-induced anemiaFibroGenPancreatic adenocarcinomaP-IIIP-IIP-IIroxadustatASP1517/FG-4592(EVRENZO)fezolinetantESN364Small moleculeNK3 receptor antagonistVasomotor symptoms associated with menopauseP-IIIresamirigene bilparvovecAT132Gene therapy(AAV-based genetherapy)MTM1 gene replacement toexpress myotubularinX-linked myotubular myopathyP-II* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.** Compounds with “In-house” in this column include ones discovered by collaborative research.Updates from the previous announcement (Oct 2021):gilteritinib (ASP2215): Entered into Phase 1 for newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy.enfortumab vedotin (ASG-22ME): Removed the description of the approval in Japan in Sep 2021 for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy.roxadustat (ASP1517/FG-4592): Removed the description of the approval in Europe in Aug 2021 for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease.Astellas has rights inJapan, Europe, theCommonwealth ofIndependent States,the Middle East, andSouth Africa.In-house(Ogeda)In-house(AudentesTherapeutics)S-19Modality / TechnologyClassificationTarget diseasePhase *Licensor **RemarksProjects with Focus Area approach (1/2)PrimaryFocusImmuno-oncologyGeneric nameCode No.(Brand name)ASP1951/PTZ-522AntibodyGITR agonistic antibodyCancerASP9801Oncolytic virusOncolytic virus carryingIL-7 and IL-12CancerASP7517Cell therapy (artificialadjuvant vector cells)WT1 loadedartificial adjuvant vector cellAcute myeloid leukemia andmyelodysplastic syndromeSolid tumorASP0739Cell therapy (artificialadjuvant vector cells)NY-ESO-1 loadedartificial adjuvant vector cellCancerASP1570Small moleculeDGKζ inhibitorCancerASP2138AntibodyAnti-Claudin 18.2 and anti-CD3bispecific antibodyGastric and gastroesophageal junctionadenocarcinoma, pancreatic adenocarcinomaBlindnessandRegenerationMitochondriaBiologyASP7317Cell therapyRetinal pigment epithelium cells Geographic atrophy secondary to age-related macularP-Idegeneration, Stargardt diseaseASP1128/MA-0217Small moleculePPARδ modulatorAcute kidney injurybocidelparASP0367/MA-0211Small moleculePPARδ modulatorPrimary mitochondrial myopathiesDuchenne muscular dystrophyP-IP-IP-IIP-IP-IP-IP-IP-IIP-IIP-IIn-house(PotenzaTherapeutics)Tottori University[Discovered throughcollaborativeresearch]RIKEN[Discovered throughcollaborativeresearch]RIKEN[Discovered throughcollaborativeresearch]In-houseXencor[Discovered throughcollaborativeresearch]In-house(Ocata Therapeutics)In-house(Mitobridge)In-house(Mitobridge)S-20Modality / TechnologyClassificationTarget diseasePhase *Licensor **RemarksProjects with Focus Area approach (2/2)PrimaryFocusGeneticregulationGeneric nameCode No.(Brand name)resamirigenebilparvovecAT132 ***AT845ASP3772(Otherprojects withFocus Areaapproach)Gene therapy(AAV-based genetherapy)Gene therapy(AAV-based genetherapy)MTM1 gene replacement toexpress myotubularinX-linked myotubular myopathyGAA gene replacement toexpress GAA enzymePompe diseaseNext generation vaccine(MAPS technology)Pneumococcal vaccine basedon a multiple antigen-presentingsystem (MAPS) platformPrevention of pneumococcal diseaseP-IIP-IP-IIP-IIP-IP-IIn-house(AudentesTherapeutics)In-house(AudentesTherapeutics)AffinivaxImmunomicTherapeutics[Discovered throughcollaborativeresearch]FX-322Small moleculeSensorineural hearing lossFrequencyTherapeuticsAstellas has rights inEx-US marketsASP0598Recombinant proteinChronic tympanic membrane perforationAuration BiotechInner ear progenitor cellactivator(combination of GSK-3 inhibitorand HDAC inhibitor)Recombinant human heparin-binding epidermal growth factor-like growth factorASP2390New generation vaccine(LAMP-Vax technology)House dust mite-induced allergic rhinitis* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.** Compounds with “In-house” in this column include ones discovered by collaborative research.*** AT132 is also listed in “XTANDI and Strategic products”.Updates from the previous announcement (Oct 2021):ASP1948: Discontinued Phase 1 program for cancer.ASP1570: Described the classification.ASP2138: Entered into Phase 1 for gastric and gastroesophageal junction adenocarcinoma and pancreatic adenocarcinoma.S-21OthersmirabegronYM178Generic nameCode No.(Brand name)peficitinibASP015KModality / TechnologyClassificationTarget diseasePhase *Licensor **RemarksSmall moleculeβ3 receptor agonistNeurogenic detrusor overactivity in pediatric patientsEuropeP-IIIIn-houseSmall moleculeJAK inhibitorRheumatoid arthritisChinaP-IIIIn-houseOveractive bladder in pediatric patientsEuropeP-IIIisavuconazoleSmall moleculeAzole antifungalUSP-IIBasileaInvasive aspergillosis and mucormycosisin pediatric patientsASP8062Small moleculeOpioid use disorderIn-houseGABAB receptor positiveallosteric modulatorAlcohol use disorderP-IIP-I* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.** Compounds with “In-house” in this column include ones discovered by collaborative research.S-22Rx+ ProgramSphere(Business area)ProgramChronicdiseaseprogressionpreventionAs of Feb 2022Underlined items indicate changes from the previous announcement in Oct 2021.Game applicationfor exercise supportSmartphone application to support exercise using motion sensing technology for peoplewho needs regular exerciseUnder developmentBANDAI NAMCOEntertainmentConceptStatus *PartnerRemarksFit-eNceService to provide scientifically evidenced exercise programs and systems supporting regular exerciseLaunched in limited areasFit-eNce HomeService to provide scientifically evidenced exercise programs and systems supporting regular exerciseat homeUnder test marketingBlueStarDigital therapeutics for adults with diabetesUnder developmentWelldocPrecision surgery-guide enabling identification of ureter in hysterectomy and colorectal surgery etc.P-IIIPatientoutcomemaximizationpudexacianiniumASP5354* The list shows the most advanced stage if the stages are different depending on the region.Updates from the previous announcement (Oct 2021):pudexacianinium (ASP5354): Added the generic name. Entered into Phase 3.EG Holter: Removed the description of the program which obtained certification in Aug 2021.S-23